glp 1 peptides GLP-1 receptor agonists show promise in treating substance use disorders Design of novel Xenopus GLP-1-based

New research from Sweden has found that GLP-1 agonist drugs used to treat diabetes and obesity are unlikely to increase thyroid cancer risk, as some previous studies had suggested.

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

Up to 65% improvement in feelings of fullness

At the end of 2025 we saw Eli Lillys Phase 3 TRIUMPH-4 trial for retatrutide read out